BK polyomavirus infection after renal transplantation: Surveillance in a resource-challenged setting

2017 ◽  
Vol 19 (6) ◽  
pp. e12770 ◽  
Author(s):  
Soumita Bagchi ◽  
Vikraman Gopalakrishnan ◽  
Sandeep Kumar Srivastava ◽  
Ashish Upadhayay ◽  
Geetika Singh ◽  
...  
2014 ◽  
Vol 03 (01) ◽  
Author(s):  
Alice Kennard Prof David W Johnson

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S650-S650
Author(s):  
Ralph Rogers ◽  
Michael Chobanian ◽  
Hannah Gilligan ◽  
Nitender Goyal ◽  
Nancy Rodig ◽  
...  

Abstract Background Reactivation of BK polyomavirus (BKPyV) due to immunosuppression after renal transplantation can lead to allograft nephropathy (BKAN) or even allograft loss. Many transplant centers implement screening protocols in an attempt to detect BKPyV reactivation before progression to BKAN, although the frequency and duration of screening vary widely among centers. Methods The New England BK Consortium (NEBKCON), a collaboration of 12 transplant centers in the northeastern United States, has adopted a standard BKPyV screening protocol (screening monthly for the first 6 months followed by screening every 3 months until 2 years after transplantation). Participating members implemented this screening protocol at their centers, and later measured adherence to the protocol as part of a NEBKCON quality improvement project. This study retrospectively analyzes BKPyV-specific outcomes in association with adherence to this protocol. Results Six centers reported data on 472 subjects who received a renal transplant between January 2016 and December 2017. Adherence to the screening protocol during the first 12 months (7.1–76.7%, mean 56.1%) and 24 months (2.9–52.5%, mean 36.8%) after transplant varied between centers. Rates of BKPyV viremia (3.6–28.2%, mean 20.6%) as well as BKAN (0–4.5%, mean 3.2%) also varied among centers. Adherence to the screening protocol was associated with a decrease in the magnitude of the initial viral load detected (3.29 vs. 3.74 log10 copies/mL, P = 0.065), but was not associated with peak viral load (3.95 vs. 4.14 log10 copies/mL, P = 0.47), viremia duration (179 vs. 196 days, P = 0.74), or incidence of BKAN among viremic subjects (15.3 vs. 16.0%, P = 0.91). Conclusion Even with a uniform screening protocol for BKPyV in place, adherence to this protocol varied widely among centers. More research is needed to determine patient-level and center-level barriers to adherence, as well as to determine optimal screening practices to further reduce the incidence of BKAN. Disclosures All authors: No reported disclosures.


2019 ◽  
Vol 103 (12) ◽  
pp. 2692-2700
Author(s):  
Yassine Bouatou ◽  
Tri Q. Nguyen ◽  
Joris J.T.H. Roelofs ◽  
Frederike J. Bemelman ◽  
Laura Michielsen ◽  
...  

Intervirology ◽  
2013 ◽  
Vol 56 (4) ◽  
pp. 249-252 ◽  
Author(s):  
Ana Carolina Jonard Zalona ◽  
Rafael Brandão Varella ◽  
Cristina Maeda Takiya ◽  
Renato Torres Goncalves ◽  
Mariano Gustavo Zalis ◽  
...  

2020 ◽  
Vol 34 (12) ◽  
Author(s):  
Seyed M. Hosseini‐Moghaddam ◽  
Qingyong Xu ◽  
Anthony M. Jevnikar ◽  
Andrew A. House ◽  
Patrick Luke ◽  
...  

2020 ◽  
Vol 142 ◽  
pp. 104036
Author(s):  
Brandon Dow Chan ◽  
Gabriella Wong ◽  
Qing Jiang ◽  
Magnolia Muk-Lan Lee ◽  
Wing-Yan Wong ◽  
...  

Author(s):  
Ying-Hsia Chu ◽  
Weixiong Zhong ◽  
William Rehrauer ◽  
Derek M Pavelec ◽  
Irene M Ong ◽  
...  

Abstract Objectives To review rare cases of BK polyomavirus (BKPyV) associated urologic carcinomas in kidney transplant recipients at one institution and in the literature. Methods We describe the clinicopathologic features of BKPyV-associated urologic carcinomas in a single-institution cohort. Results Among 4,772 kidney recipients during 1994 to 2014, 26 (0.5%) and 26 (0.5%) developed posttransplantation urothelial carcinomas (UCs) and renal cell carcinomas (RCCs), respectively, as of 2017. Six (27%) UCs but none of the RCCs expressed large T antigen (TAg). TAg-expressing UCs were high grade with p16 and p53 overexpression (P < .05 compared to TAg-negative UCs). Tumor genome sequencing revealed BKPyV integration and a lack of pathogenic mutations in 50 cancer-relevant genes. Compared to TAg-negative UCs, TAg-expressing UCs more frequently presented at advanced stages (50% T3-T4) with lymph node involvement (50%) and higher UC-specific mortality (50%). Conclusions Post-renal transplantation BKPyV-associated UCs are aggressive and genetically distinct from most non-BKPyV–related UCs.


2012 ◽  
Vol 46 (6) ◽  
pp. 466-474 ◽  
Author(s):  
Dominik Steubl ◽  
Marcus Baumann ◽  
Tibor Schuster ◽  
MichaeL Fischereder ◽  
Bernhard K. Krämer ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document